Volume 11 — November 13, 2014
ORIGINAL RESEARCH
Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States
| Age | Predicted Probability of HIV Test (95% CI) |
|---|---|
| 18 | 0.36 (0.26–0.48) |
| 19 | 0.37 (0.27–0.47) |
| 20 | 0.37 (0.27–0.47) |
| 21 | 0.37 (0.28–0.47) |
| 22 | 0.37 (0.29–0.46) |
| 23 | 0.37 (0.29–0.46) |
| 24 | 0.37 (0.30–0.46) |
| 25 | 0.37 (0.30–0.45) |
| 26 | 0.38 (0.31–0.45) |
| 27 | 0.38 (0.31–0.45) |
| 28 | 0.38 (0.32–0.45) |
| 29 | 0.38 (0.32–0.44) |
| 30 | 0.38 (0.33–0.44) |
| 31 | 0.38 (0.33–0.44) |
| 32 | 0.39 (0.33–0.44) |
| 33 | 0.39 (0.34–0.44) |
| 34 | 0.39 (0.34–0.44) |
| 35 | 0.39 (0.34–0.44) |
| 36 | 0.38 (0.34–0.43) |
| 37 | 0.38 (0.34–0.43) |
| 38 | 0.38 (0.33–0.43) |
| 39 | 0.37 (0.33–0.42) |
| 40 | 0.37 (0.32–0.41) |
| 41 | 0.36 (0.32–0.41) |
| 42 | 0.35 (0.31–0.40) |
| 43 | 0.34 (0.30–0.39) |
| 44 | 0.33 (0.29–0.37) |
| 45 | 0.31 (0.27–0.36) |
| 46 | 0.30 (0.26–0.34) |
| 47 | 0.28 (0.24–0.32) |
| 48 | 0.26 (0.23–0.32) |
| 49 | 0.24 (0.21–0.28) |
| 50 | 0.22 (0.19–0.26) |
| 51 | 0.20 (0.18–0.24) |
| 52 | 0.18 (0.16–0.21) |
| 53 | 0.17 (0.14–0.20) |
| 54 | 0.15 (0.13–0.18) |
| 55 | 0.14 (0.12–0.16) |
| 56 | 0.13 (0.11–0.15) |
| 57 | 0.12 (0.10–0.14) |
| 58 | 0.11 (0.09–0.13) |
| 59 | 0.11 (0.09–0.13) |
| 60 | 0.10 (0.09–0.12) |
| 61 | 0.10 (0.08–0.12) |
| 62 | 0.10 (0.08–0.12) |
| 63 | 0.09 (0.08–0.11) |
| 64 | 0.09 (0.07–0.11) |
Figure 1. Model-adjusted relationship between age and
human immunodeficiency virus (HIV) testing among cancer survivors aged 18 to
64 years, United States, 2009, Behavioral Risk Factor Surveillance System.
Abbreviation: CI, confidence interval.
| Age | Predicted Probability of HIV Test (95% CI) |
|---|---|
| 0 | 0.15 (0.12–0.18) |
| 1 | 0.15 (0.13–0.18) |
| 2 | 0.16 (0.13–0.18) |
| 3 | 0.16 (0.13–0.19) |
| 4 | 0.16 (0.14–0.19) |
| 5 | 0.16 (0.14–0.19) |
| 6 | 0.17 (0.14–0.19) |
| 7 | 0.17 (0.14–0.20) |
| 8 | 0.17 (0.14–0.20) |
| 9 | 0.17 (0.14–0.20) |
| 10 | 0.17 (0.15–0.20) |
| 11 | 0.17 (0.15–0.20) |
| 12 | 0.17 (0.15–0.20) |
| 13 | 0.17 (0.15–0.20) |
| 14 | 0.17 (0.15–0.20) |
| 15 | 0.17 (0.15–0.20) |
| 16 | 0.17 (0.14–0.20) |
| 17 | 0.17 (0.14–0.20) |
| 18 | 0.17 (0.14–0.20) |
| 19 | 0.17 (0.14–0.20) |
| 20 | 0.17 (0.14–0.20) |
| 21 | 0.17 (0.14–0.19) |
| 22 | 0.16 (0.14–0.19) |
| 23 | 0.16 (0.14–0.19) |
| 24 | 0.16 (0.14–0.19) |
| 25 | 0.16 (0.13–0.19) |
| 26 | 0.16 (0.13–0.19) |
| 27 | 0.16 (0.13–0.19) |
| 28 | 0.16 (0.13–0.19) |
| 29 | 0.15 (0.13–0.18) |
| 30 | 0.15 (0.13–0.18) |
| 31 | 0.15 (0.12–0.18) |
| 32 | 0.15 (0.12–0.18) |
| 33 | 0.15 (0.12–0.18) |
| 34 | 0.15 (0.12–0.18) |
| 35 | 0.15 (0.12–0.18) |
| 36 | 0.14 (0.11–0.18) |
| 37 | 0.14 (0.11–0.18) |
| 38 | 0.14 (0.11–0.18) |
| 39 | 0.14 (0.11–0.18) |
| 40 | 0.14 (0.11–0.18) |
| 41 | 0.14 (0.10–0.18) |
| 42 | 0.14 (0.10–0.18) |
| 43 | 0.13 (0.10–0.18) |
| 44 | 0.13 (0.10–0.18) |
| 45 | 0.13 (0.10–0.18) |
| 46 | 0.13 (0.10–0.18) |
| 47 | 0.13 (0.09–0.18) |
| 48 | 0.13 (0.09–0.18) |
| 49 | 0.13 (0.09–0.18) |
| 50 | 0.13 (0.09–0.18) |
| 51 | 0.12 (0.09–0.17) |
| 53 | 0.12 (0.08–0.17) |
| 54 | 0.12 (0.08–0.17) |
| 55 | 0.12 (0.08–0.17) |
| 56 | 0.12 (0.08–0.17) |
| 57 | 0.12 (0.08–0.17) |
| 58 | 0.12 (0.08–0.17) |
| 59 | 0.12 (0.08–0.17) |
| 62 | 0.11 (0.07–0.17) |
| 63 | 0.11 (0.07–0.17) |
Figure 2. Model-adjusted relationship between age and
human immunodeficiency virus (HIV) testing among cancer survivors aged 18 to
64 years, United States, 2009, Behavioral Risk Factor Surveillance System.
Abbreviation: CI, confidence interval.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.
